Creative Biolabs has ample experience in mRNA (messenger ribonucleic acid)-based methods applied in the drug design and discovery field. Currently, we can precisely design novel mRNA therapeutics with high safety, specificity, and validity. Equipped with a team of professional scientists, we have won a good reputation among our worldwide customers for accomplishing numerous challenging projects in this field. We are proud to partner with our clients on the journey of bringing novel candidate targets to the market.
mRNA, a single-stranded RNA, is usually produced in the process of transcription that plays an important role in protein synthesis and disease therapy. In general, mRNA can be created in the nucleus and be further transported into the cytoplasm to make proteins bind to specific mRNAs. Transfer RNA (tRNA) and ribosomal RNA (rRNA) are the main types of RNA molecules that are essential for forming ribosomes and mRNA transcription.
Pilot studies have demonstrated that mRNAs can mediate the gene expression of many proteins. The dysfunction of mRNA is associated with several human diseases, such as lethal congenital contracture syndrome 1 (LCCS1). Moreover, recent studies have revealed that mRNA exogenous delivery has been considered as a new group of drugs with wide applications in the treatment of rare metabolic diseases. In addition, a wide variety of vehicles and methods for mRNA delivery have been generated to improve its safety and effectiveness in multiple preclinical studies.
Fig.1 Principles of antigen-encoding mRNA pharmacology.1
Currently, mRNA has been broadly used as a powerful tool for treating various human diseases, especially for malignant tumors. Meanwhile, many advanced mRNA technologies have been established for developing novel cancer immunotherapies. At Creative Biolabs, we are dedicated to helping our worldwide customers select, design, and optimize the mRNA molecule of the target of interest. Our mRNA-based immunotherapy platform has been generated for offering a series of mRNA therapeutics development services, ranging from mRNA design, synthetic carrier optimization, to in vitro and in vivo evaluation studies. Up to now, we can provide a battery of mRNA-based immunotherapy services based on different kinds of state-of-art technologies. For instance, alternative splicing, a new type of pre-mRNA transcripts technology, has become an attractive way in our labs for creating mature mRNA and then producing peptide-MHC complex that is used in many immunotherapies, such as T cell receptor engineered T cells (TCR-T cells) therapy.
Fig.2 Schematic illustration of the development of potential immunotherapies targeting mRNA processing-derived neoantigens.2
Moreover, in recent projects, several lipid nanoparticles containing mRNA coding for specific tumor antigens have been designed as perfect tools for inducing cytotoxic CD8 T cell responses in melanoma models. The data have suggested that immunotherapy using lipid nanoparticles can strongly inhibit tumor growth and increase the overall survival of patients. Furthermore, mRNA-encoded tumor antigens have become an effective strategy for loading dendritic cells (DCs) ex vivo to trigger anti-tumor immune responses in cancer immunotherapy. Besides, mRNA prepared by in vitro transcription (IVT) has been regarded as a suitable delivery system for modified or recombinant proteins. The results collected from various tumor models have shown that IVT mRNA can be utilized in the generation of passive cellular immunotherapy.
Creative Biolabs has developed a novel mRNA-based immunotherapy platform to boost the functions of our mRNA-based drug discovery pipeline. Our approaches will remove the obstacles of your projects and bring breakthroughs to affect the future of new drug discovery. If you are interested in our services, please feel free to contact us for more information.
Inquire About Our ServicesA: mRNA-based immunotherapy involves using messenger RNA (mRNA) to instruct cells to produce specific proteins that trigger an immune response against diseases, particularly cancers. This approach harnesses the body's natural defenses to recognize and attack cancer cells by producing antigens that stimulate cytotoxic T-cell responses.
A: mRNA-based immunotherapy is advantageous due to its high specificity, rapid development, and ability to induce potent immune responses. Unlike traditional therapies, mRNA does not integrate into the genome, reducing the risk of genetic mutations. Additionally, mRNA can be quickly modified and produced, allowing for personalized and adaptable treatments.
A: Creative Biolabs provides a comprehensive mRNA-based immunotherapy platform that includes mRNA design, synthetic carrier optimization, and in vitro/in vivo evaluation studies. Their services support the development of novel cancer immunotherapies by ensuring the mRNA therapeutics are safe, effective, and tailored to the specific needs of each project.
A: Creative Biolabs utilizes advanced technologies such as alternative splicing, lipid nanoparticles for delivery, and in vitro transcription (IVT) mRNA. These technologies are employed to create effective mRNA vaccines and therapies that induce strong immune responses against targeted diseases, particularly in oncology.
A: Lipid nanoparticles are crucial in mRNA-based immunotherapy as they protect the mRNA and facilitate its delivery into target cells. Creative Biolabs uses LNPs to efficiently deliver mRNA encoding tumor antigens to induce robust immune responses, making them a key component in the development of mRNA-based cancer vaccines.
A: mRNA-based immunotherapy contributes to cancer treatment by enabling the immune system to recognize and attack cancer cells. Creative Biolabs develops mRNA therapies that encode tumor-specific antigens, leading to the activation of cytotoxic T-cells that can target and destroy cancer cells, offering a promising approach for treating various cancers.
In this study, the mRNA-based cancer immunotherapy CV9201 was designed to target non-small cell lung cancer (NSCLC) by encoding five tumor-associated antigens (TAAs). The primary goal was to induce robust immune responses against cancer cells expressing these antigens. The study involved patients with advanced NSCLC who had stable disease following first-line treatment. The results showed that CV9201 was well-tolerated, with most adverse events being mild to moderate, such as injection site reactions and flu-like symptoms. Immune responses were detected in 63% of evaluable patients, with some showing specific T-cell and antibody responses against one or more TAAs. Despite these immune responses, the clinical efficacy was modest, with a median progression-free survival of 5.0 months and overall survival of 10.8 months. These findings suggest that while CV9201 can induce immune responses, its clinical impact may need further enhancement, possibly through combination therapies.
Fig.3 The intensity of T cell response of patients was detected by ICS or IFN-γ ELISPOT after CV9201 treatment.3
| Cat. No | Product Name | Promoter |
|---|---|---|
| GTVCR-WQ0010MR | IVTScrip™ pT7-VEE-mRNA-TGFB1 Vector | T7 |
| GTVCR-WQ12MR | IVTScrip™ pT7-VEE-mRNA-Anti-S, 2130 Vector | T7 |
| GTVCR-WQ13MR | IVTScrip™ pSP6-VEE-mRNA-Anti-S, 2130 Vector | SP6 |
| GTVCR-WQ15MR | IVTScrip™ pT7-VEE-mRNA-Anti-TNFRSF17, 2857916 Vector | T7 |
| GTVCR-WQ17MR | IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF17, 2857916 Vector | SP6 |
| Cat. No | Product Name | Type |
|---|---|---|
| GTTS-WQ010MR | IVTScrip™ mRNA-β gal, 5-Methoxy-U modified (Cap 1, 30 nt-poly(A)) | Reporter |
| GTTS-WQ11MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ12MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ13MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ14MR | IVTScrip™ mRNA-Anti-S, 2130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) | Antibody |
References
